Home/Filings/4/0001562180-23-002197
4//SEC Filing

Spellman David A 4

Accession 0001562180-23-002197

CIK 0001517022other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 8:00 AM ET

Size

6.7 KB

Accession

0001562180-23-002197

Insider Transaction Report

Form 4
Period: 2023-03-01
Spellman David A
SVP, CFO and Treasurer
Transactions
  • Sale

    Common Stock

    2023-03-01$0.88/sh6,400$5,616510,860 total
  • Sale

    Common Stock

    2023-03-01$0.88/sh810$711510,050 total
Footnotes (2)
  • [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022.
  • [F2]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.

Issuer

Akebia Therapeutics, Inc.

CIK 0001517022

Entity typeother

Related Parties

1
  • filerCIK 0001733204

Filing Metadata

Form type
4
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 8:00 AM ET
Size
6.7 KB